Victoria L.M. Herrera MD
Professor, Cardiovascular Medicine
Graduate Faculty (Primary Mentor of Grad Students)
700 Albany St | (617) 638-4020
Whitaker Cardiovascular Institute
Evans Center for Interdisciplinary Biomedical Research
Victoria Herrera, MD, is a Professor of Medicine at Boston University School of Medicine, Whitaker Cardiovascular Institute, Associate Director for Medicine at BU Nanotechnology Innovation Center. Dr. Herrera is a graduate of the University of the Philippines College of Medicine - magna cum laude, and former Visiting International Fellow at Harvard University Graduate School of Arts and Sciences. She completed Pediatrics Residencey at Univerfity of Massachusetts Medical Center and Boston Children's Hospital, Harvard Medical School; Fellowship in Pediatric Cardiology and Molecular Cardiology at Boston Children's Hospital, Harvard Medical School, and Hypertension Molecular Genetics at Boston University School of Medicine. Dr. Herrera serves as reviewer for Journals and for the NIH: former CVB Cardiovascular Study Section member, Hypertension Study Section, and current ad hoc reviewer for Cancer BioTherapeutics and Development SBIR Study Section. Dr. Herrera is co-inventor in multiple patents on novel targeted therapies for cancer and stroke, and nanodelivery systems.
As an NIH physician scientist awardee, research interests focus on the understanding of molecular bases of complex diseases via translational research coupled with animal modeling that recapitulate complex disease phenotypes respectively with spontaneous progression to end-organ disease and comorbidities. These animal modeling insights provide novel approaches to identification and testing of novel therapeutic and/or theranostic paradigms prioritized for their respective potentials to become clinically relevant game changers. Research expertise span the integration of basic and clinical sciences, translation of nanotechnologies into nanomedicines, and the design of clinically relevant preclinical and translational efficacy and safety studies relevant to novel approaches for ARDS, Covid19-ARDS, stroke, cardiovascular disease and cancer.
A graduate of the University of the Philippines College of Medicine, Dr. Herrera served as the founding scientific advisor to the Philippine General Hospital Child Protection Unity and the Child Protection Network in the Philippines.
MD, University of the Philippines, 1978
BS, University of the Philippines, 1974
Herrera VLM, Walkey AJ, Nguyen MQ, Gromisch CM, Mosaddhegi JZ, Gromisch MS, Jundi B, Lukassen S, Carstensen S, Denis R, Belkina AC, Baron RM, Pinilla-Vera M, Muller M, Kimberly WT, Goldstein JN, Lehmann I, Shih AR, Eils R, Levy BD, Ruiz-Opazo N. Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target. Res Sq. 2021 Sep 13. PMID: 34545358.Published on 4/14/2021
Gromisch CM, Tan GLA, Pasion KA, Moran AM, Gromisch MS, Grinstaff MW, Carr FJ, Herrera VLM, Ruiz-Opazo N. Humanized anti-DEspR IgG4S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis ratnu/nu model. BMC Cancer. 2021 Apr 14; 21(1):407. PMID: 33853558.Published on 9/11/2018
Herrera VL, Colby AH, Ruiz-Opazo N, Coleman DG, Grinstaff MW. Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells. Nanomedicine (Lond). 2018 08; 13(16):2083-2098. PMID: 30204054.Published on 2/9/2017
Colby AH, Oberlies NH, Pearce CJ, Herrera VL, Colson YL, Grinstaff MW. Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 May; 9(3). PMID: 28185434.Published on 2/1/2017
Colby AH, Berry SM, Moran AM, Pasion KA, Liu R, Colson YL, Ruiz-Opazo N, Grinstaff MW, Herrera VL. Highly Specific and Sensitive Fluorescent Nanoprobes for Image-Guided Resection of Sub-Millimeter Peritoneal Tumors. ACS Nano. 2017 02 28; 11(2):1466-1477. PMID: 28099801.Published on 1/1/2017
Colby AH, Oberlies NH, Pearce CJ, Herrera V, Colson YL, Grinstaff M. Cover Image, Volume 9, Issue 3. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2017; 9(3):e1474.Published on 1/1/2017
Colby AH, Oberlies NH, Pearce C, Herrera V, Colson YL, Grinstaff M. Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle: Nanoparticle drug-delivery systems for peritoneal cancers. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2017; 9(3):e1451.Published on 11/11/2016
Matsuura S, Patterson S, Lucero H, Leiva O, Grant AK, Herrera VL, Ravid K. In vivo magnetic resonance imaging of a mouse model of myelofibrosis. Blood Cancer J. 2016 11 11; 6(11):e497. PMID: 27834941.Published on 6/14/2016
Herrera VL, Steffen M, Moran AM, Tan GA, Pasion KA, Rivera K, Pappin DJ, Ruiz-Opazo N. Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein. BMC Mol Biol. 2016 Jun 14; 17(1):15. PMID: 27301377.Published on 4/14/2016
Herrera VL, Colby AH, Tan GA, Moran AM, O'Brien MJ, Colson YL, Ruiz-Opazo N, Grinstaff MW. Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis. Nanomedicine (Lond). 2016 May; 11(9):1001-15. PMID: 27078118.